Calcium channel blockers: Resolving the controversy

Norman M Kaplan

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Ongoing controversies about the use of calcium channel blockers (CCBs) have caused major agitations in patients and physicians' management of hypertension. The controversy about short-acting nifedipine has highlighted the inappropriate use of this agent for indications that were never approved. However, the other elements of the controversy have no scientific basis and do not in any way incriminate the appropriate use of long-acting CCBs. Prospective, controlled studies are now available documenting the safety of long-acting CCBs and additional large-scale trials are in progress.

Original languageEnglish (US)
Pages (from-to)567-572
Number of pages6
JournalDrugs of Today
Volume32
Issue number7
StatePublished - 1996

Fingerprint

Calcium Channel Blockers
Nifedipine
Prospective Studies
Hypertension
Physicians
Safety

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology (medical)
  • Pharmacology

Cite this

Calcium channel blockers : Resolving the controversy. / Kaplan, Norman M.

In: Drugs of Today, Vol. 32, No. 7, 1996, p. 567-572.

Research output: Contribution to journalArticle

Kaplan, NM 1996, 'Calcium channel blockers: Resolving the controversy', Drugs of Today, vol. 32, no. 7, pp. 567-572.
Kaplan, Norman M. / Calcium channel blockers : Resolving the controversy. In: Drugs of Today. 1996 ; Vol. 32, No. 7. pp. 567-572.
@article{0acabe84e57147858873e47753d87077,
title = "Calcium channel blockers: Resolving the controversy",
abstract = "Ongoing controversies about the use of calcium channel blockers (CCBs) have caused major agitations in patients and physicians' management of hypertension. The controversy about short-acting nifedipine has highlighted the inappropriate use of this agent for indications that were never approved. However, the other elements of the controversy have no scientific basis and do not in any way incriminate the appropriate use of long-acting CCBs. Prospective, controlled studies are now available documenting the safety of long-acting CCBs and additional large-scale trials are in progress.",
author = "Kaplan, {Norman M}",
year = "1996",
language = "English (US)",
volume = "32",
pages = "567--572",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "7",

}

TY - JOUR

T1 - Calcium channel blockers

T2 - Resolving the controversy

AU - Kaplan, Norman M

PY - 1996

Y1 - 1996

N2 - Ongoing controversies about the use of calcium channel blockers (CCBs) have caused major agitations in patients and physicians' management of hypertension. The controversy about short-acting nifedipine has highlighted the inappropriate use of this agent for indications that were never approved. However, the other elements of the controversy have no scientific basis and do not in any way incriminate the appropriate use of long-acting CCBs. Prospective, controlled studies are now available documenting the safety of long-acting CCBs and additional large-scale trials are in progress.

AB - Ongoing controversies about the use of calcium channel blockers (CCBs) have caused major agitations in patients and physicians' management of hypertension. The controversy about short-acting nifedipine has highlighted the inappropriate use of this agent for indications that were never approved. However, the other elements of the controversy have no scientific basis and do not in any way incriminate the appropriate use of long-acting CCBs. Prospective, controlled studies are now available documenting the safety of long-acting CCBs and additional large-scale trials are in progress.

UR - http://www.scopus.com/inward/record.url?scp=0029768557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029768557&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0029768557

VL - 32

SP - 567

EP - 572

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 7

ER -